尼塞韦单抗与呼吸道合胞病毒细支气管炎住院
该前瞻性、多中心、匹配病例对照研究纳入12月龄以下婴儿1035例,其中病例组690例(因RSV相关细支气管炎住院),匹配对照组345例(因非RSV感染相关疾病就诊)。病例组60例(8.7%)和对照组97例(28.1%)先前接受过尼塞韦单抗。尼塞韦单抗对RSV相关细支气管炎住院的调整有效性为83.0%(95%CI 73.4-89.2),对需重症监护的RSV相关细支气管炎有效性为69.6%(95%CI 42.9-83.8),对需通气支持的RSV相关细支气管炎有效性为67.2%(95%CI 38.6-82.5)。敏感性分析结果与主要分析相似。
要点
- 在12月龄以下婴儿中,尼塞韦单抗对RSV相关细支气管炎住院的调整有效性为83.0%(95%CI 73.4-89.2)。
- 尼塞韦单抗对需重症监护的RSV相关细支气管炎有效性为69.6%(95%CI 42.9-83.8)。
- 尼塞韦单抗对需通气支持的RSV相关细支气管炎有效性为67.2%(95%CI 38.6-82.5)。
- 病例组8.7%(60/690)与对照组28.1%(97/345)先前接受过尼塞韦单抗。
适用人群与场景
- 12月龄以下婴儿;病例为2023年10月15日至12月10日因RSV相关细支气管炎住院的婴儿;对照为同一医院因非RSV感染相关疾病就诊的婴儿。
研究设计与关键结果
- 前瞻性、多中心、匹配病例对照研究,纳入1035例婴儿,病例组690例(中位年龄3.1月,四分位距1.8-5.3),匹配对照组345例(中位年龄3.4月,四分位距1.6-5.6),按年龄、就诊日期和研究中心以2:1比例匹配。
- 尼塞韦单抗对RSV相关细支气管炎住院的调整有效性为83.0%(95%CI 73.4-89.2)。
- 尼塞韦单抗对需重症监护的RSV相关细支气管炎有效性为69.6%(95%CI 42.9-83.8),病例组27/193例(14.0%)vs 匹配对照组47/146例(32.2%)。
- 尼塞韦单抗对需通气支持的RSV相关细支气管炎有效性为67.2%(95%CI 38.6-82.5),病例组27/189例(14.3%)vs 匹配对照组46/151例(30.5%)。
- 敏感性分析结果与主要分析相似。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、匹配病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在真实世界环境中,尼塞韦单抗能有效降低RSV相关细支气管炎住院风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.
METHODS: We conducted a prospective, multicenter, matched case-control study to analyze the effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis in infants younger than 12 months of age. Case patients were infants younger than 12 months of age who were hospitalized for RSV-associated bronchiolitis between October 15 and December 10, 2023. Control patients were infants with clinical visits to the same hospitals for conditions unrelated to RSV infection. Case patients were matched to control patients in a 2:1 ratio on the basis of age, date of hospital visit, and study center. We calculated the effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis (primary outcome) by means of a multivariate conditional logistic-regression model with adjustment for confounders. Several sensitivity analyses were performed.
RESULTS: The study included 1035 infants, of whom 690 were case patients (median age, 3.1 months; interquartile range, 1.8 to 5.3) and 345 were matched control patients (median age, 3.4 months; interquartile range, 1.6 to 5.6). Overall, 60 case patients (8.7%) and 97 control patients (28.1%) had received nirsevimab previously. The estimated adjusted effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis was 83.0% (95% confidence interval [CI], 73.4 to 89.2). Sensitivity analyses gave results similar to those of the primary analysis. The effectiveness of nirsevimab therapy against RSV-associated bronchiolitis resulting in critical care was 69.6% (95% CI, 42.9 to 83.8) (27 of 193 case patients [14.0%] vs. 47 of 146 matched control patients [32.2%]) and against RSV-associated bronchiolitis resulting in ventilatory support was 67.2% (95% CI, 38.6 to 82.5) (27 of 189 case patients [14.3%] vs. 46 of 151 matched control patients [30.5%]).
CONCLUSIONS: In a real-world setting, nirsevimab therapy was effective in reducing the risk of hospitalized RSV-associated bronchiolitis. (Funded by the National Agency for AIDS Research-Emerging Infectious Disease and others; ENVIE ClinicalTrials.gov number, NCT06030505.).
参考来源
- Assad Z, Romain AS, Aupiais C, et al. Nirsevimab and Hospitalization for RSV Bronchiolitis. N Engl J Med. 2024. PMID: 38986058. doi:10.1056/NEJMoa2314885
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。